Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma
✍ Scribed by A. BALDAN; D. MARINO; M. DE GIORGIO; C. ANGONESE; U. CILLO; A. D'ALESSANDRO; A. MASOTTO; M. MASSANI; M. MAZZUCCO; E. MIOLA; D. NERI; D. PACCAGNELLA; G. PIVETTA; A. STELLATO; L. TOMMASI; F. TREMOLADA; A. TUFANO; G. ZANUS; F. FARINATI; ON BEHALF OF GENE – GRUPPO EPATOCARCINOMA NORD-EST
- Book ID
- 108604773
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 139 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
We read with interest the paper by Di Martino et al. published in the December 2004 issue of HEPATOLOGY 1 that examines estrogen-related effects on hepatitis C fibrosis. Specifically, progression of hepatitis C fibrosis was correlated with prior pregnancies, menopausal status, past use of oral contr
## Abstract ## BACKGROUND Radiofrequency ablation (RFA) was introduced recently as a therapeutic modality for hepatocellular carcinoma (HCC), an alternative to percutaneous ethanol injection therapy (PEIT), which is coming into use worldwide. Previously reported treatment efficacy and complication
## Abstract ## Background A recent small study reported a high rate of neoplastic seeding after cooled-tip radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) in patients who had undergone previous needle biopsy. Tumour seeding was associated with subcapsular tumour location, poorly d